Literature DB >> 26833153

OligoG CF-5/20 Disruption of Mucoid Pseudomonas aeruginosa Biofilm in a Murine Lung Infection Model.

Wang Hengzhuang1, Zhijun Song2, Oana Ciofu3, Edvar Onsøyen4, Philip D Rye4, Niels Høiby5.   

Abstract

Biofilm growth is a universal survival strategy for bacteria, providing an effective and resilient approach for survival in an otherwise hostile environment. In the context of an infection, a biofilm provides resistance and tolerance to host immune defenses and antibiotics, allowing the biofilm population to survive and thrive under conditions that would destroy their planktonic counterparts. Therefore, the disruption of the biofilm is a key step in eradicating persistent bacterial infections, as seen in many types of chronic disease. In these studies, we used both in vitro minimum biofilm eradication concentration (MBEC) assays and an in vivo model of chronic biofilm infection to demonstrate the biofilm-disrupting effects of an alginate oligomer, OligoG CF-5/20. Biofilm infections were established in mice by tracheal instillation of a mucoid clinical isolate of Pseudomonas aeruginosa embedded in alginate polymer beads. The disruption of the biofilm by OligoG CF-5/20 was observed in a dose-dependent manner over 24 h, with up to a 2.5-log reduction in CFU in the infected mouse lungs. Furthermore, in vitro assays showed that 5% OligoG CF-5/20 significantly reduced the MBEC for colistin from 512 μg/ml to 4 μg/ml after 8 h. These findings support the potential for OligoG CF-5/20 as a biofilm disruption agent which may have clinical value in reducing the microbial burden in chronic biofilm infections.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26833153      PMCID: PMC4862494          DOI: 10.1128/AAC.01721-15

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

Review 1.  Bacterial biofilms: a common cause of persistent infections.

Authors:  J W Costerton; P S Stewart; E P Greenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

2.  Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors.

Authors:  Morten Hentzer; Hong Wu; Jens Bo Andersen; Kathrin Riedel; Thomas B Rasmussen; Niels Bagge; Naresh Kumar; Mark A Schembri; Zhijun Song; Peter Kristoffersen; Mike Manefield; John W Costerton; Søren Molin; Leo Eberl; Peter Steinberg; Staffan Kjelleberg; Niels Høiby; Michael Givskov
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

3.  Epidemiological investigations of the respiratory tract bacteriology in patients with cystic fibrosis.

Authors:  N Hoiby
Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol       Date:  1974-08

4.  An in vitro study of alginate oligomer therapies on oral biofilms.

Authors:  J L Roberts; S Khan; C Emanuel; L C Powell; M F Pritchard; E Onsøyen; R Myrvold; D W Thomas; K E Hill
Journal:  J Dent       Date:  2013-07-30       Impact factor: 4.379

5.  Novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis.

Authors:  Nadine Hoffmann; Thomas Bovbjerg Rasmussen; Peter Østrup Jensen; Charlotte Stub; Morten Hentzer; Søren Molin; Oana Ciofu; Michael Givskov; Helle Krogh Johansen; Niels Høiby
Journal:  Infect Immun       Date:  2005-04       Impact factor: 3.441

6.  Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting.

Authors:  O Ciofu; V Fussing; N Bagge; C Koch; N Høiby
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

7.  Pseudomonas aeruginosa infection in cystic fibrosis. Bactericidal effect of serum from normal individuals and patients with cystic fibrosis on P. aeruginosa strains from patients with cystic fibrosis or other diseases.

Authors:  N Holby; S Olling
Journal:  Acta Pathol Microbiol Scand C       Date:  1977-04

8.  Experimental chronic Pseudomonas aeruginosa lung infection in rats. Non-specific stimulation with LPS reduces lethality as efficiently as specific immunization.

Authors:  K H Lange; H P Hougen; N Høiby; A Fomsgaard; J Rygaard; H K Johansen
Journal:  APMIS       Date:  1995-05       Impact factor: 3.205

9.  Azithromycin blocks quorum sensing and alginate polymer formation and increases the sensitivity to serum and stationary-growth-phase killing of Pseudomonas aeruginosa and attenuates chronic P. aeruginosa lung infection in Cftr(-/-) mice.

Authors:  Nadine Hoffmann; Baoleri Lee; Morten Hentzer; Thomas Bovbjerg Rasmussen; Zhijun Song; Helle Krogh Johansen; Michael Givskov; Niels Høiby
Journal:  Antimicrob Agents Chemother       Date:  2007-07-09       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of antibiotics in biofilm infections of Pseudomonas aeruginosa in vitro and in vivo.

Authors:  Wang Hengzhuang; Niels Høiby; Oana Ciofu
Journal:  Methods Mol Biol       Date:  2014
View more
  15 in total

1.  Antibiofilm Efficacy of Nitric Oxide-Releasing Alginates against Cystic Fibrosis Bacterial Pathogens.

Authors:  Mona Jasmine R Ahonen; Jamie M Dorrier; Mark H Schoenfisch
Journal:  ACS Infect Dis       Date:  2019-06-11       Impact factor: 5.084

2.  A Low-Molecular-Weight Alginate Oligosaccharide Disrupts Pseudomonal Microcolony Formation and Enhances Antibiotic Effectiveness.

Authors:  Manon F Pritchard; Lydia C Powell; Alison A Jack; Kate Powell; Konrad Beck; Hannah Florance; Julian Forton; Philip D Rye; Arne Dessen; Katja E Hill; David W Thomas
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

3.  A glycopolymer improves vascoelasticity and mucociliary transport of abnormal cystic fibrosis mucus.

Authors:  Courtney M Fernandez-Petty; Gareth W Hughes; Hannah L Bowers; John D Watson; Bradley H Rosen; Stacy M Townsend; Carlo Santos; Caroline E Ridley; Kengyeh K Chu; Susan E. Birket; Yao Li; Hui Min Leung; Marina Mazur; Bryan A Garcia; T Idil Apak Evans; Emily Falk Libby; Heather Hathorne; Justin Hanes; Guillermo J Tearney; John P Clancy; John F Engelhardt; William E Swords; David J Thornton; William P Wiesmann; Shenda M Baker; Steven M Rowe
Journal:  JCI Insight       Date:  2019-04-18

Review 4.  Virulence Factors of Pseudomonas Aeruginosa and Antivirulence Strategies to Combat Its Drug Resistance.

Authors:  Chongbing Liao; Xin Huang; Qingxia Wang; Dan Yao; Wuyuan Lu
Journal:  Front Cell Infect Microbiol       Date:  2022-07-06       Impact factor: 6.073

5.  The antimicrobial effects of the alginate oligomer OligoG CF-5/20 are independent of direct bacterial cell membrane disruption.

Authors:  Manon F Pritchard; Lydia C Powell; Saira Khan; Peter C Griffiths; Omar T Mansour; Ralf Schweins; Konrad Beck; Niklaas J Buurma; Christopher E Dempsey; Chris J Wright; Philip D Rye; Katja E Hill; David W Thomas; Elaine L Ferguson
Journal:  Sci Rep       Date:  2017-03-31       Impact factor: 4.379

6.  Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides.

Authors:  Lydia C Powell; Manon F Pritchard; Elaine L Ferguson; Kate A Powell; Shree U Patel; Phil D Rye; Stavroula-Melina Sakellakou; Niklaas J Buurma; Charles D Brilliant; Jack M Copping; Georgina E Menzies; Paul D Lewis; Katja E Hill; David W Thomas
Journal:  NPJ Biofilms Microbiomes       Date:  2018-06-29       Impact factor: 7.290

Review 7.  Bacterial biopolymers: from pathogenesis to advanced materials.

Authors:  M Fata Moradali; Bernd H A Rehm
Journal:  Nat Rev Microbiol       Date:  2020-01-28       Impact factor: 60.633

8.  Genome Sequence of Pseudomonas aeruginosa Strain DK1-NH57388A, a Stable Mucoid Cystic Fibrosis Isolate.

Authors:  Anders Norman; Oana Ciofu; Cristina Isabel Amador; Niels Høiby; Lars Jelsbak
Journal:  Genome Announc       Date:  2016-02-25

9.  Evaluation of Biofilm Formation and Frequency of Multidrug-resistant and Extended Drug-resistant Strain in Pseudomonas aeruginosa Isolated from Burn Patients in Isfahan.

Authors:  Pourya Nasirmoghadas; Sima Yadegari; Sharareh Moghim; Bahram Nasr Esfahani; Hossein Fazeli; Farkhondeh Poursina; Seyed Abolfazl Hosseininassab; Hajieh Ghasemian Safaei
Journal:  Adv Biomed Res       Date:  2018-04-24

10.  Exploiting Mannuronan C-5 Epimerases in Commercial Alginate Production.

Authors:  Anne Tøndervik; Olav A Aarstad; Randi Aune; Susan Maleki; Philip D Rye; Arne Dessen; Gudmund Skjåk-Bræk; Håvard Sletta
Journal:  Mar Drugs       Date:  2020-11-18       Impact factor: 5.118

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.